| Position 2007 (2006) | Therapeutric category (code) | No of products 2006 (2005) |
|---|---|---|
| 1 (1) | Anticancer, other (K6Z) | 1158 (1093) |
| 2 (2) | Anticancer, immunological (K3) | 618 (616) |
| 3 (3) | Antidiabetic (A10B) | 394 (344) |
| 4 (5) | Analgesic, other (N2Z) | 355 (337) |
| 5 (4) | Prophylactic vaccine (J7A1) | 332 (341) |
| 6 (6) | Cardiovascular (C9Z) | 325 (323) |
| 7 (7) | Cognition enhancer (N6D) | 307 (296) |
| 8 (9) | Anti-inflammatory (M1A1) | 268 (267) |
| 9 (13) | GI inflammatory/bowel disorders (A16) | 262 (242) |
| 10 (8) | Antiasthma (R8A) | 255 (275) |
| 11 (10) | Recombinant vaccine (T2B) | 251 (261) |
| 12 (11) | Antiviral, other (J5Z) | 245 (245) |
| 13 (15) | Ophthalmological (S1Z) | 245 (224) |
| 14 (12) | Neuroprotective (N7C) | 230 (245) |
| 15 (14) | Immunosuppressant (I5) | 227 (236) |
| 16 (17) | Hypolipaemic/antiatherosclerosis (C10) | 224 (197) |
| 17 (21) | Antiarthritic, other (M2Z) | 201 (179) |
| 18 (-) | Monoclonal antibody, other (T3A9) | 201 (-) |
| 19 (-) | Formulation, fixed-dose combination (F9B) | 197 (-) |
| 20 (24) | Symptomatic antidiabetic (A10C) | 191 (171) |
| 21 (16) | Gene therapy (T4A) | 191 (200) |
| 22 (22) | Antiparkinsonian (N4A) | 188 (178) |
| 23 (20) | Urological (G4Z) | 188 (187) |
| 24 (18) | Antiarthritic, immunological (M2C) | 186 (194) |
| 25 (-) | Monoclonal antibody, fully-human (T3A2) | 184 (-) |
| Table 3: Top 25 therapeutic categories for R&D | ||